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Abstract
Introduction: Febrile neutropenia (FN) is common in cancer patients receiving myelotoxic therapy. The procedures
to treat FN are well established in oncology, but it is unclear whether management is adequate in the emergency
department (ED).
Methods: This prospective, multicentre, observational study was carried out in 47 French EDs for 6 months. Patients
were adults presenting at the ED with FN after myelotoxic treatment for cancer. Severity of infection was defined
according to Bone criteria for severe sepsis and septic shock (SS/SSh) and risk was determined according to
Multinational Association of Supportive Care in Cancer (MASCC) criteria. The end point was the implementation of
guidelines. Management of patients with SS/SSh required: (i) adequate intravenous (IV) antimicrobial therapy for the
first 90 min (broad-spectrum beta-lactam with or without an aminoglycoside); (ii) fluid challenge (500 mL); (iii) lactate
measurement; (iv) at least one blood culture; and (v) hospitalization. Management of patients without SS/SSh
required: (1) no initiation of granulocyte - cell stimulating factor (G-CSF); (2) adequate IV antimicrobial therapy (broad-
spectrum beta-lactam) and hospitalization if the patient was high-risk according to MASCC criteria; (3) adequate oral
antimicrobial therapy (quinolone or amoxicillin/clavulanate or cephalosporin) and hospital discharge if the patient
was low-risk.
Results: 198 patients were enrolled; 89 patients had SS/SSh, of whom 19 received adequate antimicrobial therapy
within 90 min and 42 received appropriate fluid challenge. Blood cultures were obtained from 87 and lactate
concentration was measured in 29. Overall, only 6 (7%) patients with SS/SSh received adequate management.
Among 108 patients without SS/SSh, 38 (35%) were high-risk and 70 (65%) low-risk. In the high-risk group,
adequate antimicrobial therapy was given to 31 patients, G-CSF was initiated in 4 and 35 were hospitalized. In the
low-risk group, 4 patients received adequate oral antimicrobial therapy, IV antimicrobial therapy was prescribed in
59, G-CSF was initiated in 12 and six patients were discharged. Adequate management was given to 26/38 (68%)
high-risk and 1/70 low-risk patients. Factors associated with adequate management were absence of SS/SSh
(P = 0.0009) and high-risk according to MASCC criteria (P < 0.0001).
Conclusions: In this French sample of cancer patients presenting to the ED with FN, management was often
inadequate and severity was under-evaluated in the critically ill.
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The occurrence of febrile neutropenia in cancer patients
should lead to cautious severity assessment in order to
provide appropriate management and therefore improve
prognosis [1]. Despite specific recommendations, febrile
neutropenia is still associated with high morbidity and
mortality [2] and elevated health-related costs. The
underlying conditions associated with febrile neutropenia
make patients more vulnerable. Cancer itself compro-
mises survival [3], impairs innate and adaptative immu-
nity, and patients have a higher chance of developing a
nosocomial infection [4]. Therefore, severe infections are
common in this population. To help physicians safely
decide the site of care for patients with febrile neutro-
penia, criteria have been determined [5], and sensitive
scoring systems have been validated to limit patients’
misclassification [6]. In this setting, Multinational Asso-
ciation for Supportive Care in Cancer (MASCC) criteria
were developed to help physicians make decisions about
the site of care and overall management of patients with
febrile neutropenia. This score mainly relies on subjective
criteria such as the evaluation of clinical symptoms and
hydration state.
Sepsis, severe sepsis and septic shock were defined
15 years ago as a continuum of increasing severity of
the host response to the pathogen [3] closely related to
predisposition, organ failure and systemic response, and
to the microorganism and site of infection [7]. Manage-
ment of septic patients has significantly improved over
the past decade as a result of consensus guidelines pub-
lished by 11 scientific societies [8-10]. These recommen-
dations have been widely disseminated, but detecting
patients at risk remains a daily challenge in emergency
medicine.
The presence of cancer may impair the prognosis of
acute patients [8], including septic patients [11] visiting
the emergency department (ED) [12]. Reports on the
management of febrile neutropenia in EDs are scarce,
retrospective and mainly single centre studies. Interest-
ingly, a French survey based on declarative question-
naires reported that 1 out of 31 cancer teams involved
emergency physicians in their organizational strategy to
manage patients with febrile neutropenia [13]. As the
incidence of sepsis has increased in the general popula-
tion [14], more patients visit the ED for this reason [15]
and this had led to a dramatic increase in number of
cancer patients in this setting [16].
This study was carried out to describe the manage-
ment of patients with febrile neutropenia in EDs and to
determine how management complies with recommen-
dations. The secondary objective was to determine the
factors associated with adequate management.
Materials and methods
Study design and ethics
This was a prospective multicentre study carried out in
47 French EDs over a six-month period (4 February to
4 August, 2008). The inform consent from patients was
required for this study. The study protocol and patient
information procedures were approved by the institu-
tional review board for the protection of human subjects
of the Cochin Port-Royal (Paris, France).
Recruitment of patients
Patients were included if they were adults (>18 years old)
who presented at a participating ED with febrile neutro-
penia after myelotoxic treatment for cancer. Delay between
last cytotoxic treatment and occurrence of febrile neutro-
penia was not pre-specified to enter the study. Definition of
febrile neutropenia consisted of a white blood cell count
less than 1,000/μL( o rn e u t r o p h i l s< 5 0 0 / μL), with a core
temperature above 8.3°C (or >38°C on two consecutive
occasions). Patients who presented with febrile neutropenia
in another setting or who refused to participate were not
included in the study.
Procedure and data collection
An investigator (SA) contacted by phone the team lea-
der of each participating centre to describe the study
and explain criteria for eligibility. Each team leader gave
the information about this study to the ED team. The
physician on duty invited eligible patients to participate
and implemented the electronic form. As this was an
observation study, data were collected on the basis of
usual practices.
The characteristics of each participating centre were
recorded, with special reference to the management of
febrile neutropenia. Data collected for each patient
included demographic characteristics, physical data and
medical history focusing on cancer and outcome (dis-
charge, admission, admission to an ICU, death).
Study objectives
The primary objective was to describe the management
of patients with febrile neutropenia in EDs and to deter-
mine whether management complies with recommenda-
tions. The secondary objective was to determine the
factors associated with adequate management.
Evaluation criteria in the guidelines were identified to
accurately assess the primary end points. Patients with feb-
rile neutropenia were divided into two groups: those with
and those without severe sepsis or septic shock (SS/SSh).
Patients with SS/SSh were selected according to the
following criteria [9,17]: blood lactate more than
4 mmol/L, or low blood pressure before fluid challenge
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usual systolic blood pressure), or at least one organ dys-
function (pulse oxymetry [SpO2] <95% with fraction of
inspired oxygen >0.5, blood creatinine >176 μmol/L or
oliguria, international normalised ratio >2, bilirubinemia
>78 μmol/L, Glasgow Coma Scale <15). Thrombopenia
was excluded from the criteria because of the potential
effect of chemotherapy on platelet counts. Patients with-
out SS/SSh were identified as high risk or low risk
according to the MASCC classification [6] (Table 1). Of
note, data that allowed determination of MASCC and
presence of SS/SSh were collected at the bedside by
attending physicians. Implementation of the database
was not intended to help physicians detecting the sever-
ity of a patient’s condition.
Implementation of the following guidelines was
assessed. Management of patients with SS/SSh required
for the 90 first minutes [9,10]: (i) a dose regimen of ade-
quate (broad-spectrum) intravenous antimicrobial ther-
apy; (ii) fluid challenge (500 mL) if mean arterial blood
pressure was less than 65 mmHg; (iii) lactate measure-
ment; (iv) at least one blood culture; and (v) hospitaliza-
tion. Management of patients without SS/SSh who were
high risk according to MASCC criteria required [18-20]:
(i) adequate intravenous antimicrobial agent (broad-spec-
trum beta-lactam with or without an aminoglycoside); (ii)
no initiation of granulocyte-cell stimulating factor
(G-CSF); and (iii) hospitalization. Management of
patients without SS/SSh who were low-risk according to
MASCC criteria required [18-20]: (i) adequate oral anti-
microbial agent (quinolone or amoxicillin/clavulanate or
cephalosporin); (ii) no initiation of G-CSF; and (iii) hospi-
tal discharge.
Patients were divided into two groups; those managed
according to recommendations and those who were not,
irrespective of initial severity. The two populations were
compared to determine the factors associated with ade-
quate management.
Statistical analysis
Quantitative variables are described as the mean ± standard
deviation or median (range) and quantitative variables as
number and percent. The adequacy of management accord-
ing to recommendations was determined for the two sub-
groups using Pearson’s chi-squared test or Fisher’s exact
test for qualitative variables and the Student’s t test or Wil-
coxon rank sum test for quantitative variables. All tests
were two-sided. A P value of less than 5% were considered
statistically significant. All statistical analyses were carried
out using R software (Vienna University of Economics and
Business, 1090 Vienna, Austria).
Results
Emergency departments
The 47 participating EDs were distributed across France
and were representative of each metropolitan region.
Thirteen (28%) centres were tertiary teaching hospitals,
six (13%) were in the Paris area and 29 (60%) had a
dedicated unit for cancer patients. The median number
of hospital beds was 500 (range, 150 to 2900) and the
median number of ED visits was 17,679 during the six
months of the study (range, 3,000-39,045). A written
procedure for the management of febrile neutropenia
was present in 19 EDs (40%) and was formalised with
oncologists/haematologists in 15 (32%). This procedure
referred to protective isolation in 10 (21%), antimicrobial
agents in 16 (34%) and growth factors in 5 (11%) EDs.
Study participants and febrile neutropenia
Among the 777,876 patients who visited the EDs during
the study period, 198 fulfilled the inclusion criteria
(mean age 61 ± 14 years, 116 (60%) male) corresponding
to one case every 3,930 visits; all these patients accepted
to participate (Figure 1). Thirteen centres included five
patients or more (Tables 2 and 3).
A solid neoplasm was reported in 111 patients (56%)
and haematological cancer in 87 (44%). Seventy-four
patients (39%) had an underlying disorder. Patients
often self-referred to the ED (n = 87, 44%). Forty-seven
(24%) patients were treated with G-CSF to prevent neu-
tropenia and 174 (88%) had one or more risk factors
that should have prompted the prophylactic use of
G-CSF (Table 4).
The characteristics of the patients are summarised in
Table 5. Median delay between chemotherapy and ED
visit was 10 days, ranging from 4 to 35 days. According
to the criteria selected for disease severity, 89 (45%)
patients had SS/SSh, 108 (55%) did not have SS/SSh and
one could not be classified.
Among the 89 patients with SS/SSh, ED physicians
recognised the severity signs in 45 (55%). Blood cultures
were obtained from 87 (98%) patients and lactate con-
centration was measured in 29 (32%). Antimicrobial
Table 1 Classification according to the Multinational
Association for Supportive Care in Cancer(MASCC) [6]
Variables Points
(Low-risk if score >20)
Burden of illness
Age < 60 years 2
Outpatient status 3
No chronic obstructive pulmonary disease 4
No previous fungal infection 4
Clinical state at admission
No or mild symptoms 5
Moderate symptoms 3
Systolic blood pressure <90 mmHg 5
No dehydration needing perfusion 3
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within 90 minutes in 19 of 86 (22%) patients (data miss-
ing for three). Among these patients, nine (10%)
also received an aminoglycoside. Appropriate fluid chal-
lenge was given to 43 (49%) patients and 88 were hospi-
talised (99%), including 18 who were admitted to
the ICU. Only six (7%) patients with SS/SSh received
adequate management (Table 6). Of note, G-CSF
was initiated in the ED in 12 patients (14%) with
SS/SSh.
There were 108 patients without SS/SSh: 38 were high
risk (35%) and 70 were low risk (65%) according to
MASCC criteria. In the high-risk category, adequate
antimicrobial therapy was given to 31 (81%) patients,
G-CSF was initiated in the ED in four (10%) and 35
(95%) were hospitalised. In the low-risk category, four
(6%) patients received an adequate oral antimicrobial
agent, but an IV antimicrobial agent was prescribed in
59 (84%) cases. G-CSF was initiated in the ED in
12 (17%) patients. Only six patients (9%) were dis-
charged; the remaining patients were believed to have
been admitted. Adequate management was proposed in
27 of 108 (25%) patients without SS/SSh, 26 (68%) high-
risk patients and one low-risk patient (Table 2).
The 33 (17%) patients who were given adequate man-
agement were compared with the 161 (83%) patients
managed inadequately (important data were missing in
four patients that were excluded from the analysis).
Patients without SS/SSh were significantly more likely to
receive adequate management than those with SS/SSh
(P = 0.00009). On the other hand, adequate manage-
ment was proposed in 32 of 103 high-risk patients (31%)
whereas only 1 low-risk patient out of 91 (P < 0.0001)
was treated according to recommendations (Table 7).
Figure 1 Flow chart of patients included in the study.
Table 2 Characteristics of participating centres
Variables Number (%)
Mean (range)
Participating centres: 47
Tertiary teaching hospitals 13 (27%)
General community hospitals 35 (74%)
Number of beds in hospital 500 (150-2,900)
Number of ED visits during the study period 17,679 (3,000-
39,045)
Number of included patients: 198
Tertiary teaching hospitals 111 (56%)
General community hospitals 87 (44%)
Number of centres with ≥ 5 patients 13 (27%)
Written procedure for the management of febrile
neutropenia
19 (40%)
Formalised with oncologists/haematologists
Protective isolation 15 (79%)
Antimicrobial agents 10 (53%)
Prescription of G-CSF 16 (84%)
ED, emergency department; G-CSF, granulocyte-cell stimulating factor.
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Hospital centres Number of
inclusions
Number of ED visits
during study period
Presence of
cancer unit
Management procedure for
febrile neutropenia
(01) Ain: CH Bourg-en-Bresse 2 15,500 Yes Yes
(03) Allier: CH Vichy 1 15,700 No No
(06) Alpes Maritimes: CHU Nice 2 34,300 Yes No
(07) Ardèche: CH Annonay 2 11,000 No Yes
(07) Ardèche: CH Aubenas 1 ND Yes No
(09) Ariège: CH Val d’Ariège 1 13,200 No No
(13) Bouches-du-Rhône: CH Martigues 3 16,991 No No
(15) Cantal: CH Aurillac 2 12,444 Yes No
(15) Cantal: CH Mauriac 1 3,000 No No
(17) Charente-Maritime: CH La Rochelle 3 21,500 No No
(17) Charente-Maritime: CH Rochefort sur mer 3 10,500 ND ND
(19) Corrèze: CH Tulles 1 9,000 No No
(22) Côtes d’Armor: CH St Brieuc 2 22,500 Yes Yes
(24) Dordogne: CH Périgueux 2 14,900 No Yes
(26) Drôme: CH Valence 5 19,130 Yes Yes
(28) Eure-et-Loire: CH Chartres 2 19,336 Yes No
(35) Ile-et-Vilaine: CH St Malo 1 18,000 Yes Yes
(36) Indre: CH Le Blanc 1 4,570 ND ND
(37) Indre-et-Loire: CH Chinon 3 6,857 Yes Yes
(37) Indre-et-Loire: CHU Tours 8 24,000 Yes Yes
(38) Isère: CHU Grenoble 5 35,600 Yes Yes
(40) Landes: CH Mont-de-Marsan 5 ND Yes No
(42) Loire: CHU St Etienne 13 20,232 Yes No
(44) Loire Atlantique: CH Chateaubriant 1 7,000 No No
(45) Loiret: CH Montargis 4 15,222 Yes Yes
(45) Loiret: CH Orléans 6 19,500 Yes No
(47) Lot-et-Garonne: CH Agen 1 10,000 No No
(49) Maine-et-Loire: CHU Angers 4 23,882 Yes Yes
(54) Meurthe-et-Moselle: CH Lunéville 1 8,200 No No
(59) Nord: CH Dunkerque 6 26,156 Yes Yes
(62) Pas de Calais: CH St Omer 1 ND ND ND
(63) Puy de Dôme: CH Thiers 1 6,000 No No
(63) Puy de Dôme: CHU Clermont Ferrand 4 22,000 Yes No
(64) Pyrénnées Atlantiques: CH Bayonne 2 15,000 Yes Yes
(64) Pyrénnées Atlantiques: CH Pau 2 13,000 Yes No
(71) Saône-et-Loire: CH Mâcon 1 17,025 Yes ND
(72) Sarthre: CH Le Mans 1 28,643 Yes Yes
(75) Paris: CHU Cochin 22 23,368 Yes Yes
(75) Paris: CHU Hôtel Dieu 3 22,586 Yes Yes
(75) Paris: CHU Pitié 9 39,045 Yes No
(75) Paris: CHU Saint Antoine 1 23,710 Yes Yes
(75) Paris: CHU Saint Louis 38 16,948 Yes Yes
(75) Paris: CHU Tenon 5 22,261 No No
(79) Deux Sèvres: CH Niort 1 17,700 Yes No
(81) Tarn: CH Albi 3 14,587 No No
(91) Essonne: CH Longjumeau 6 15,000 Yes Yes
(94) Créteil: CHU Henri Mondor 5 22,783 Yes No
ED, emergency department, ND, not determined.
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The results of this study suggest that cancer patients
with febrile neutropenia visiting the ED are likely to pre-
sent with SS/SSh, and their management does not com-
ply with current guidelines especially in those with more
severe infections.
The 47 participating centres were distributed across
France and presented heterogeneous characteristics. This
was representative of French EDs overall. As only 60% of
hospitals had a dedicated cancer unit, it was assumed
that cancer patients with febrile neutropenia visited com-
munity hospitals with this acute adverse event. This sug-
gests that procedures to treat these patients should be
available in every ED. However, only 40% of participating
centres reported a written protocol for the management
of febrile neutropenia. A total of 198 consecutive patients
with febrile neutropenia were included in the study. The
demographic characteristics of these patients corre-
sponded to epidemiologic data published by the French
Institute Survey for cancer [16].
EDs are first dedicated to the management of patients
with severe disorders including severe infections.
A recent study reported that SS/SSh accounted for
more than 500,000 visits annually in US EDs [21]. In
addition, the incidence of severe sepsis is increasing
[22], cancer is a predisposing factor for sepsis, and the
number of cancer patients will almost double within
one decade [23]. Optimising prevention of febrile neu-
tropenia is therefore an important part of the manage-
ment. Forty-seven (24%) patients were treated with
Table 4 Prescription of G-CSF
Variables Number (%)
Prophylactic prescription of G-CSF before referral in ED 47 (24)
Age >65 years 14 (30)
Recurrent or resistant cancer 28 (60)
Chemotherapy at high-risk for neutropenia (risk >20%) 15 (38)
Previous history of febrile neutropenia 15 (32)
Prescription of G-CSF initiated in ED 27 (19)
Patients with severe sepsis 12 (44)
ED, emergency department; G-CSF, granulocyte-cell stimulating factor.
Table 5 Characteristics of the patients
Total population Patients with severe sepsis Patients without severe sepsis P
Number of patients 198 89 108
Age (years), mean ± SD 61 ± 14 65 ± 13 57 ± 14 <0.001
Female, n (%) 79 (41) 30 (34) 49 (46) 0.11
Karnofsky index, median (range) 70 (30-100) 70 (30-100) 80 (30-100) 0.06
Underlying disorders, n (%) 73 (38) 36 (43) 37 (35) 0.32
Chronic pulmonary disease 9 (12) 6 (16) 3 (3)
Chronic heart failure 12 (16) 9 (24) 3 (3)
Cirrhosis 7 (9) 4 (11) 3 (3)
Hemodialysis chronic renal failure 2 (3) 2 (5) 0
Severe neurological disorder 3 (4) 1 (3) 2 (2)
Other 51 (69) 21 (57) 30 (29)
Haematological neoplasm, n (%) 87 (44) 40 (45) 47 (44) 0.84
Lymphoproliferation 64 (32) 30 (34) 34 (31)
Myeloproliferation 22 (11) 10 (11) 12 (11)
Undetermined 1 0 1
Solid cancer 111 (56) 49 (55) 61 (56)
Lung 39 (20) 24 (27) 15 (14)
Breast 26 (13) 9 (10) 17 (16)
Urological and genital 18 (9) 9 (10) 9 (8)
Gastro-intestinal 13 (7) 5 (6) 7 (6)
Other or undetermined 15 (8) 1 8 (7)
Presence of metastasis or uncontrolled 133 (67) 69 (78) 63 (58) 0.004
Previous history of febrile neutropenia 60 (31) 24 (27) 36 (35) 0.32
Chemotherapy at high-risk for neutropenia 36 (23) 15 (21) 21 (25) 0.57
Corticosteroids 83 (42) 37 (42) 46 (43) 0.89
Prophylaxis with G-CSF 47 (25) 18 (20) 29 (28) 0.22
Antimicrobial therapy prior to ED 48 (25) 15 (17) 33 (31) 0.03
MASCC <20 (high-risk) 105 (53) 67 (75) 38 (35) <0.001
Results are expressed as number (%), mean ± standard deviation (SD), or median (range). P values below 0.05 are statistically significant.
ED, emergency department; G-CSF, granulocyte-cell stimulating factor; MASCC, Multinational Association for Supportive Care in Cancer.
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174 (88%) had one or more risk factors that should have
prompted the prophylactic use of G-CSF [24]. In our
sample, there was an under-use of G-CSF in patients at
risk of febrile neutropenia. The under-use of G-CSF in
oncology practice was also reported previously by Hayes
[25]. We therefore believe that emergency physicians
will have increasing chances to treat febrile neutropenia.
In their series used to derive and validate the Mortal-
ity in Emergency Department Sepsis (MEDS) score, Sha-
piro and colleagues reported that 35.5% and 2.5% of
patients visiting the ED with infection had severe sepsis
and septic shock, respectively [12]. Here we reported
that 89 (45%) patients with febrile neutropenia pre-
sented with SS/SSh. This underscores that chemother-
apy-related neutropenia in cancer patients is a risk
factor for developing severe infection. In our series, very
few patients that developed severe infections were trea-
ted according to current guidelines. Indeed, adequate
management was initiated in only six patients. This may
suggest that detecting severe infections is challenging
for emergency physicians. Initial severity assessment is
sometimes falsely reassuring and patients may worsen
during their stay in the ED [26]. A study conducted in
Brazil [14] reported that ED physicians were able to
detect severe infection in 15.8% of cases. Implementa-
tion of the Surviving Sepsis Campaign guidelines
improved detection of severe infections but 61.5% of
patients remained under-treated because of inadequate
assessment. Measuring lactate concentration has been
recommended to help physicians detect [26] and man-
age severe infections [27]. We observed that lactate was
infrequently measured in the present series. Therefore,
procedures to optimise detection of severe infection
were partially applied in our patients that did not seem
to be perceived as severely ill.
A burden of evidence supports the paramount role of
early recognition and prompt management of severe
infection, and admission to the ICU when applicable
[27]. The prognosis of patients with severe infection
actually depends on their initial management; that is,
treatment received in the ED for half of patients [28].
We observed that few patients received adequate antimi-
crobial therapy or fluid challenge in an appropriate
time-span. We therefore conclude that patients with
severe infection were under-treated. Similar findings
were reported in a large Spanish study [29], as an
incredibly low rate of patients admitted with SS/SSh
received process-of-care according to bundles, even after
an educational program involving physicians and nurses
of the ED and ICU. An inadequate initial assessment
may result from difficulties to correctly implement
guidelines in a busy ED. First, equipment and physi-
cians’ skills to provide complex technical procedures to
patients vary betwen hospitals [30]. Barriers can also be
related to time consumption of procedures necessary to
implement procedures for severe infections. In addition,
all team leaders are not fully confident in guidelines to
treat severe infections [31]. However, we checked fluid
loading and delay to first antimicrobial agent that do
not require specific skills or organisation. We observed
that these basic treatments were not correctly delivered.
In a series of sepsis with hypotension, the delay to anti-
microbial agents was over six hours in more than half of
patients because infection was not recognised. We
believe that most patients were not treated according to
guidelines because initial assessment failed to detect the
severity of disease.
Despite the efforts in the past decade to produce and
distribute specific guidelines for treating severe infec-
tion, difficulties persist to detect SS/SSh even in typically
at-risk patients such as those with febrile neutropenia.
Table 6 Characteristics of the management of febrile neutropenia in patients with or without severe sepsis
Management in the ED Patients with severe sepsis Patients without severe sepsis
(n = 89) High risk
(n = 38)
Low risk
(n = 70)
Adequate antimicrobial therapy 28 (32) 30 (81) 31 (44)
Supportive treatment
Fluid challenge 43 (49) 5 (14) 6 (9)
Vasoactive drugs 6 (7) 0 (0) 0 (0)
Laboratory data
Lactate concentration 29 (33) 1 (3) 11 (16)
Blood cultures 87 (99) 36 (100) 63 (93)
New prescription of G-CSF 12 (14) 4 (11) 12 (17)
Adequate orientation 88 (99) 35 (95) 6 (9)
Global adequate management 6 (7) 26 (68) 1 (1)
Risk of patients without severe sepsis was determined using MASCC criteria (low risk if MASCC ≥ 20; high risk if MASCC <20). All results are expressed as number
(%). ED, emergency department; G-CSF, granulocyte-cell stimulating factor; MASCC, Multinational Association for Supportive Care in Cancer.
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prognosis in patients presenting infection with severity
criteria [32]. Guidelines to treat patients with SS/SSh
endorse that first dose of antibiotics should be given in
a timespan shorter than 90 minutes [9]. Whereas it can
be assumed that earlier antimicrobial agents would
improve prognosis in febrile neutropenia, no evidence
can currently lead to any recommendations about delay.
Consequently, guidelines to treating patients with febrile
neutropenia are not clear regarding delays to treatment;
therefore, objectives are easier to obtain. This may partly
explain why management of patients without SS/SSh
frequently reached goals.
A puzzling result is that supportive care was not mod-
ified by the intervention of the oncologist or haemato-
logist: the presence of a medical unit dedicated to
Table 7 Factors associated with adequate management
Variables Adequate management
(n = 33)
Inadequate management
(n = 161)
P
Tertiary teaching hospital Yes 24 (12) 92 (88) 0.1
No 9 (21) 68 (79)
Number of ED visits during study period <20 000 17 (18) 78 (82) 0.80
≥ 20 000 15 (16) 76 (84)
Unit for cancer patients Yes 29 (18) 132 (82) 1
No 4 (15) 22 (85)
Written procedures for febrile neutropenia management Yes 24 (21) 92 (79) 0.16
No 9 (13) 62 (87)
Age (mean ± SD) 58 ± 17 61 ± 14 0.30
Sex Male 17 (15) 97 (85) 0.29
Female 16 (21) 61 (79)
Karnosfsky index (median (range)) 70 (30-100) 80 (30-100) 0.07
Place of stay Home 30 (18) 139 (82) 0.23
House care 2 (40) 3 (60)
Underlying disorder Yes 12 (17) 60 (83) 0.78
No 21 (18) 94 (82)
Type of cancer Haematological 14 (17) 70 (83) 0.91
Solid cancer 19 (17) 91 (83)
Presence of metastasis or uncontrolled Yes 22 (17) 108 (83) 0.96
No 11 (17) 53 (83)
Antimicrobial therapy prior to ED Yes 9 (9) 39 (91) 0.75
No 24 (17) 119 (83)
Time of ED visit Day 18 (15) 102 (85) 0.24
Night 15 (22) 54 (78)
Level of nurse triage <3 20 (22) 73 (78) 0.43
≥ 3 8 (16) 42 (84)
Presence of severity signs according to ED physician Yes 9 (17) 45 (83) 0.82
No 24 (18) 109 (82)
Severe sepsis Yes 6 (7) 80 (93) 0.0009
No 27 (25) 81 (75)
Cancer specialist advice Yes 14 (17) 70 (83) 0.95
No 18 (17) 88 (83)
MASCC classification High risk 32 (31) 71 (69) <0.001
Low risk 1 (1) 90 (99)
Protective isolation Yes 29 (19) 128 (81) 0.50
No 4 (13) 26 (87)
Surgical management Yes 2 (50) 2 (50) 0.12
No 26 (15) 146 (85)
Adequate orientation Agree 26 (17) 129 (83) 0.65
Disagree 7 (20) 28 (80)
Values shown are number and percentage unless stated otherwise. P values below 0.05 are statistically significant.
ED, emergency department; G-CSF, granulocyte-cell stimulating factor; MASCC, Multinational Association for Supportive Care in Cancer; SD, standard deviation.
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Page 8 of 11cancer in the same hospital, the existence of written
procedures about febrile neutropenia, or the oncologist’s
advice did not improve the quality of care. Despite
recent validation studies, the relevance of MASCC to
guide site of care can be limited because several corner-
stone items are missing from this evaluation tool [18].
This supports the fact that the assessment of severity of
infection in a short time-span appears to be particularly
challenging in onco-haematological patients [33].
The study has several limitations. Whereas simplicity of
the study design presumably improved acceptability and
feasibility, we cannot rule out that patients could be
missed because making clinical research around the
clock is sometimes difficult in busy EDs. Our study did
not follow up the patients. It was decided to carry out a
descriptive study and patients’ outcomes were not
recorded. Thus, it is unknown whether the prognosis of
the patients with febrile neutropenia would have changed
if recommendations had been implemented. In addition,
the study was proposed to 350 French hospitals, but only
47 took part. Therefore, results could have been biased
because EDs that participated were possibly more
involved in the management of patients with sepsis and/
or cancer. However, these centres were geographically
distributed across France and were representative of
French EDs because they were mostly set in general hos-
pitals. In addition, only 19 Eds had a written procedure
for febrile neutropenia. The convenience series was also
limited because no patient waived the invitation to parti-
cipate in this prospective study. Another limitation was
the use of MASCC criteria to decide on the site of care
and antimicrobial therapy because this score has never
been validated in the ED setting. Stratification of patients
using the MASCC scoring system is debatable as consen-
sus meetings suggest that it is not superior to expert
advice. However, the MASCC classification has been reg-
ularly used as a gold standard to stratify patients with
febrile neutropenia. In addition MASCC calculation
depends on the burden of the onco-haematological disor-
der. However, it is usually accepted that patients with
advanced cancer under-estimate the severity of the disor-
der [34,35]. As emergency physicians usually obtain past
medical history from patients’ interviews, they may mis-
classify severity of febrile neutropenia when assessed by
MASCC level. Finally, we found that patients with more
severe and mild febrile neutropenia were inadequately
treated according to a univariate analysis. We were
unable to identify risk factors for inadequate manage-
ment by a multivariate analysis, partly because of the size
of the sample.
Conclusions
Patients with febrile neutropenia who visit the EDs are
likely to develop severe infection. In this sample,
patients who met our definition of SS/SSh had a low
rate of being treated with adequate fluid and a low rate
of evaluation with serum lactate level. Patients who
were considered to be low risk were often admitted to
the hospital rather than being discharged home on oral
antibiotics. More work is needed within the standard
operation protocols of EDs as well as outcome-based
research to optimise care for these patients.
Key messages
￿ Patients with febrile neutropenia are likely to pre-
sent to the ED with severe infections.
￿ More severe patients are poorly recognised and
under-treated.
￿ Patients with mild disorders are over-treated.
￿ Patients with febrile neutropenia presenting to the
ED are usually not treated according to guidelines.
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